

This communication should be viewed by:

Clinical staff
Facility/Practice staff

Pharmaceutical Policies Updates Effective June 1, 2023

MVP Health Care® (MVP) would like to make you aware of Pharmaceutical Policies updates effective June 1, 2023.

To view all current MVP Medical policies, *Sign In* at mvphealthcare.com/providers and select *Resources*, then *Medical Policies*. All policies are reviewed at least once annually. This communication lists all impacted policies and their statuses. Policies fall into one of the following categories:

- **New** – Denotes a new policy
- **Updated** – Updated policies have content changes that may affect coverage criteria for services and/or drugs
- **Reviewed/No Changes**– Policies that have been reviewed but have no content change
- **Archived** – Denotes a policy that is no longer active

The following policies are effective June 1, 2023 and will be available for review on or before May 1, 2023. Hard copies of the policies are available upon request.

Pharmaceutical Policy Name	Status
Mail Order	Updated
Dupixent	Updated
Valchlor	Updated
Onychomycosis	Updated
Cosmetic Drug Agents	Updated
Adalimumab	Updated
Luxturna	Reviewed/No Changes
Lidocaine (topical) products	Archived
Topical Agents for Pruritis	Reviewed/No Changes
Parsabiv	Reviewed/No Changes
Effective April 1, 2023	Status
Diclofenac (topical products)	Updated
Select Hypnotics	Updated

To view all communications, visit mvphealthcare.com/FastFax

Questions? Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-684-9286.

